Use of a Liver-specific Promoter Reduces Immune Response to the Transgene in Adenoviral Vectors
Overview
Affiliations
Previous studies using adenoviral (Ad) vectors expressing human alpha1-antitrypsin (hAAT) under the control of ubiquitous promoters (RSV, mPGK) elicited the production of antibodies to hAAT in some mouse strains (C3H/HeJ and BALB/c) but not in others (C57BL/6J). In contrast, when a helper-dependent Ad vector (AdSTK109) with all viral coding sequences deleted and expressing hAAT from human genomic DNA with the endogenous promoter was used, C3H/HeJ mice failed to develop antibodies and demonstrated long-term expression. These results suggested that promoter choice and/or properties of the vector itself might influence the host immune response to the transgene product. Direct comparison of first-generation vectors expressing the hAAT cDNA from a ubiquitous mouse PGK promoter rather than from a liver-specific mouse albumin promoter demonstrated that an antibody response to hAAT occurred with the mPGK promoter but not with the albumin promoter in C3H/HeJ mice. As expected, neither vector elicits an antibody response in C57BL/6J mice. Coinjection of the two first-generation vectors containing the mPGK and albumin promoter in C3H/HeJ mice induced an antibody response with resulting loss of detectable hAAT from the sera of the injected mice in 3-4 weeks. From these data, we conclude that under certain conditions, the choice of promoter with its associated liver-specific expression can modulate the host immune response to the transgene independent of viral backbone.
Adenoviral Vectors for Gene Therapy of Hereditary Diseases.
Muravyeva A, Smirnikhina S Biology (Basel). 2025; 13(12.
PMID: 39765719 PMC: 11673936. DOI: 10.3390/biology13121052.
Strategies for Modifying Adenoviral Vectors for Gene Therapy.
Muravyeva A, Smirnikhina S Int J Mol Sci. 2024; 25(22).
PMID: 39596526 PMC: 11595218. DOI: 10.3390/ijms252212461.
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases.
Lin C, Greenblatt M, Gao G, Shim J Hum Gene Ther. 2024; 35(9-10):317-328.
PMID: 38534217 PMC: 11302315. DOI: 10.1089/hum.2024.022.
Trevisan B, Rodriguez M, Medder H, Lankford S, Combs R, Owen J Front Immunol. 2022; 13:1070476.
PMID: 36532079 PMC: 9755880. DOI: 10.3389/fimmu.2022.1070476.
Evading the AAV Immune Response in Mucopolysaccharidoses.
Piechnik M, Sawamoto K, Ohnishi H, Kawamoto N, Ago Y, Tomatsu S Int J Mol Sci. 2020; 21(10).
PMID: 32414007 PMC: 7279460. DOI: 10.3390/ijms21103433.